Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration

Glaucia N. M. Hajj1,2, Fernanda F.da Silva1, Bárbara de Bellis1, Fernanda C. S. Lupinacci1, Hermo M. Bellato1, Juvanier R. Cruz3, Cláudionor N. C. Segundo4, Igor V. Faquini4,6, Leuridan C. Torres3,5, Paulo I. Sáematsu6, Maria D. Begnami7, Vilma R. Martins1,2 and Martín Roffé1,2

1 International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil
2 National Institute of Science and Technology in Oncogenomics, São Paulo, Brazil
3 Department of Clinical Oncology, Hospital do Câncer de Pernambuco, Recife, Brazil
4 Department of Neurosurgery, Hospital da Restauração, Recife, Brazil
5 Translational Research Laboratory Prof. C. A. Hart, Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil
6 Department of Neurosurgery, A.C. Camargo Cancer Center, São Paulo, Brazil
7 Department of Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil

Keywords
gene signature; glioma; immune infiltrate; LAPTM5; mesenchymal subtype; RSK

Correspondence
M. Roffé, International Research Center, A.C. Camargo Cancer Center, Rua Taguá, 440, São Paulo, SP, Brazil
Tel: +55 11 2189 5000 e. 2977
E-mail: mroffe@accamargo.org.br

(Received 20 September 2019, accepted 6 November 2019, available online 11 December 2019)
doi:10.1002/1878-0261.12595

The p90 ribosomal S6 kinase (RSK) family, a downstream target of Ras/extracellular signal-regulated kinase signaling, can mediate cross-talk with the mammalian target of rapamycin complex 1 pathway. As RSK connects two oncogenic pathways in gliomas, we investigated the protein levels of the RSK isoforms RSK1–4 in nontumoral brain (NB) and grade I–IV gliomas. When compared to NB or low-grade gliomas (LGG), a group of glioblastomas (GBMs) that excluded long-survivor cases expressed higher levels of RSK1 (RSK1hi). No difference was observed in RSK2 median-expression levels among NB and gliomas; however, high levels of RSK2 in GBM (RSK2hi) were associated with worse survival. RSK4 expression was not detected in any brain tissues, whereas RSK3 expression was very low, with GBM demonstrating the lowest RSK3 protein levels. RSK1hi and, to a lesser extent, RSK2hi GBMs showed higher levels of phosphorylated RSK, which reveals RSK activation. Transcriptome analysis indicated that most RSK1hi GBMs belonged to the mesenchymal subtype, and RSK1 expression strongly correlated with gene expression signature of immune infiltrates, in particular of activated natural killer cells and M2 macrophages. In an independent cohort, we confirmed that RSK1hi GBMs exclude long survivors, and RSK1 expression was associated with high protein levels of the mesenchymal subtype marker lysosomal protein transmembrane 5, as well as with high expression of CD68, which indicated the presence of infiltrating immune cells. An RSK1 signature was obtained based on differentially expressed mRNAs and validated in public glioma datasets. Enrichment of RSK1 signature followed glioma progression, recapitulating RSK1 protein expression, and was associated with worse survival not only in GBM but also in LGG. In conclusion, both RSK1 and RSK2 associate with glioma malignity, but displaying

Abbreviations
ACCCC, A.C. Camargo Cancer Center; CL, classical; DEG, differentially expressed gene; ERK, extracellular signal-regulated kinase; FFPE, formalin-fixed, paraffin-embedded; GBM, glioblastoma; G-CIMP, glioma CpG island methylator phenotype; GSVA, Gene set variation analysis; HCP, Hospital do Câncer de Pernambuco; HR, Hospital da Restauração; IDH, isocitrate dehydrogenase; IHHC, immunohistochemistry; LAPTM5, lysosomal protein transmembrane 5; LGG, low-grade glioma; ME, mesenchymal; mTORC1, mammalian target of rapamycin complex 1; NB, nontumoral brain; NK, natural killer cells; NL, neural; PN, proneural; RPPA, reverse-phase protein array; RSK, p90 ribosomal S6 kinase; TCGA, The Cancer Genome Atlas; TMA, tissue microarray.
isoform-specific peculiarities. The progression-dependent expression and association with immune infiltration suggest RSK1 as a potential progression marker and therapeutic target for gliomas.

1. Introduction

Gliomas are tumors of the central nervous system resulting from the malignant transformation of glial cells, their intermediate precursors, and neural stem cells (Huse and Holland, 2010; Zong et al., 2015). Gliomas are classified into different grades (I–IV) according to their histological characteristics (Louis et al., 2016). High-grade gliomas, III and IV, are considered malignant (Lienhart et al., 2008). The incidence of malignant gliomas is 17 000 new cases per year (Omuro and DeAngelis, 2013). Astrocytomas are the most common type of gliomas. In particular, grade IV astrocytoma, also called glioblastoma (GBM, formerly called GBM multiforme), represents 82% of malignant gliomas. GBM is highly lethal, with the average patient surviving only 12–15 months. Standard treatment involves surgical resection when possible, but because of its infiltrative nature, GBMs cannot be completely removed. Therefore, adjuvant treatment, consisting of radiotherapy and chemotherapy with the alkylating agent temozolomide, is performed after surgery. Nevertheless, almost all GBMs eventually recur and the mean disease progression time after treatment is 6.9 months (Omuro and DeAngelis, 2013).

The Cancer Genome Atlas (TCGA) and other similar initiatives applied high-throughput genomic techniques to hundreds of GBMs and low-grade gliomas (LGG; grades II and III) (Ceccarelli et al., 2016). These efforts resulted in numerous molecular classifications of gliomas. For GBMs, TCGA proposed an initial classification into four molecular subtypes (classical, mesenchymal, proneural, and neural) based on transcriptome data (Verhaak et al., 2010). The isocitrate dehydrogenase gene 1 and 2 (IDH1/IDH2) mutational status and the hypermethylation phenotype [glioma CpG island methylator phenotype (G-CIMP)], both characteristic of secondary GBMs and associated with longer survival times, were then considered to improve the TCGA classification (Noushimaehr et al., 2010; Turkalp et al., 2014). Analysis of GBMs together with LGG essentially divided gliomas into IDH mutant (consisting of most LGG and secondary GBMs) and IDH wild-type (mostly primary GBMs) (Ceccarelli et al., 2016). Later on, TCGA eliminated the neural subtype classification for GBMs. Despite all these efforts, only a limited amount of the generated information was translated to patients. A few prognostic markers are considered for GBM, including IDH1 mutation status (Turkalp et al., 2014).

It was observed that 88% of GBMs show alterations in at least one of the major components of the receptor tyrosine kinase/phosphatidylinositol-3 kinase/protein kinase B/mammalian target of rapamycin complex 1 (mTORC1) signaling pathways (Akhavan et al., 2010). Ras/extracellular signal-regulated kinase (ERK) signaling is also frequently altered in GBMs, and one of the main causes is the loss of neurofibromin 1 in 18% of patients (Akhavan et al., 2010). A direct target of ERK signaling is the p90 kDa ribosomal protein S6 kinase family (RSK). In humans, there are four isoforms of RSK with a high degree of homology (RSK1–4) (Anjum and Blenis, 2008). RSKs can phosphorylate various substrates, and it has been suggested that RSKs mediate cross-talk between the Ras/ERK and mTORC1 pathways. RSKs are known to be important in several cancers, controlling processes such as proliferation, mRNA translation, and survival (Houles and Roux, 2018). Despite its strategic position between two important oncogenic pathways in GBMs, very little is known about the role of RSK in gliomas. It was reported that mesenchymal subtype GBMs showed a marginal increase in phosphorylated RSK1 (T359/S363) relative to proneural GBMs (Brennan et al., 2013). RSK2 is thought to be a target of miR-218 and a regulator of GBM migration and invasion (Mathew et al., 2015; Sulzmaier et al., 2016). However, the last article failed to exclude any involvement of the other RSK isoforms. Moreover, the use of a nonspecific RSK inhibitor (BI-D1870 (Roffé et al., 2015)) could mislead the correct interpretation of RSK2 involvement (Sulzmaier et al., 2016). Considering the potential of RSKs as important modulators of oncogenic pathways, we aimed to comprehensively characterize the expression of RSK family isoforms in gliomas and underscore its implications.

2. Materials and methods

2.1. Glioma patient cohorts

Formalin-fixed paraffin-embedded (FFPE) samples of astrocytomas of different grades (I–IV) treated at the A.C.Camargo Cancer Center (ACCCC), São Paulo,
Characterizing gliomas with high RSK1 expression levels

2.2. Immunohistochemistry

Immunohistochemistry (IHC) was performed as previously described (Alvarenga et al., 2013). Briefly, sections were deparaffinized and hydrated and epitope retrieval was performed in a pressure cooker. Nonspecific staining was blocked by the use of Dako Protein Block (Dako, Agilent, Santa Clara, CA, USA). Sections were incubated with anti-RSK1 (sc-231; Santa Cruz Biotechnology, Dallas, TX, USA) at 1 : 200 dilution, anti-RSK2 (#9340; Cell Signaling, Danvers, MA, USA) at 1 : 50 dilution, anti-RSK3 (sc-1431; Santa Cruz) at 1 : 100 dilution, anti-P(S380)-RSK (#9341; Cell Signaling) at 1 : 25 dilution, anti-CD68 (sc-70763; Santa Cruz Biotechnology) at 1 : 100 dilution, anti-lysosomal protein transmembrane 5 (LAPTMS; Abcam, Cambridge, UK) at 1 : 50 dilution, and anti-IDH1R132H (DIA-H09; Dianova, Hamburg, Germany) at 1 : 100 dilution, in 1% BSA in PBS for 18 h at 4 °C in a humidity chamber. Secondary antibody staining was performed using EnVision + Dual Link (Dako). Color was developed by DAB. As positive controls, we included tissues with known protein expression and the primary antibody was omitted for negative controls. Quantification of HSCORE was digitally made by Aperio ScanScope XT (Leica, Buffalo Grove, IL, USA) as previously described (Alvarenga et al., 2013). Briefly, each pixel was classified as negative (0), weakly positive (1), positive (2), or strongly positive (3). The number of pixels in each category was then counted and a HSCORE was calculated according to the formula

\[ \text{HSCORE} = \sum (i \times P_i), \]

where \( P_i \) = percentage of positive pixels, varied from 0% to 100%, and pixel staining intensity \( i \) = 0, 1, 2, or 3 (Hatanaka et al., 2003). For IDH1R132H IHC, samples with no staining were considered wild-type, and when staining of any intensity was observed, the samples were considered IDH1 mutant (Machado et al., 2018). For CD68 staining, the % of strongly labeled pixels was measured.

2.3. Western blot

Fresh glioma samples were processed after surgery without a freezing step. The GBM cell line LN-18 (ATCC® CRL-2610, Manassas, VA, USA) was used as a control. LN-18 cells were serum-starved for 48 h followed by 10% serum treatment for 15 min. LN-18 cells were also transfected to express HA-RSK3 or HA-RSK4 as in Roffé et al. (2015). Tissue and cell extracts were obtained and used for western blot as in Roffé et al. (2015). In the case of tissue samples, the lysates were performed with the help of a polytron. The antibodies for RSK1, RSK2, RSK3, and P(S380)-RSK were the same of the IHC. Additional antibodies were as follows: RSK4 (sc-100424; Santa Cruz), P(S227)-RSK2 (#9341; Cell Signaling), PTEN (#9559; Cell Signaling), and ERK1/2 (#9102; Cell Signaling).

2.4. Immunohistofluorescence

For multiplex immunohistofluorescence, the Opal™ 4-Color Manual Kit (PerkinElmer, Waltham, MA, USA) was used according to the manufacturer's instructions. Briefly, slides were deparaffinized and rehydrated and epitope retrieval was performed by microwave in AR6 buffer. Endogenous peroxidase activity and nonspecific binding were blocked. Incubation with primary antibodies (CD68; Santa Cruz, sc-70763, 1 : 5000; LAPTMS; ab108017; Abcam, Cambridge, UK) at 1 : 50 dilution, and anti-IDH1R132H (DIA-H09; Dianova, Hamburg, Germany) at 1 : 100 dilution, in 1% BSA in PBS for 18 h at 4 °C in a humidity chamber. Secondary antibody staining was performed using EnVision + Dual Link (Dako). Color was developed by DAB. As positive controls, we included tissues with known protein expression and the primary antibody was omitted for negative controls. Quantification of HSCORE was digitally made by Aperio ScanScope XT (Leica, Buffalo Grove, IL, USA) as previously described (Alvarenga et al., 2013). Briefly, each pixel was classified as negative (0), weakly positive (1), positive (2), or strongly positive (3). The number of pixels in each category was then counted and a HSCORE was calculated according to the formula

\[ \text{HSCORE} = \sum (i \times P_i), \]

where \( P_i \) = percentage of positive pixels, varied from 0% to 100%, and pixel staining intensity \( i \) = 0, 1, 2, or 3 (Hatanaka et al., 2003). For IDH1R132H IHC, samples with no staining were considered wild-type, and when staining of any intensity was observed, the samples were considered IDH1 mutant (Machado et al., 2018). For CD68 staining, the % of strongly labeled pixels was measured.

2.5. HTA 2.0 microarray processing and analysis

mRNA from the 30 GBM samples from the ACCCC cohort was extracted from FFPE slices using the
ReliaPrep™ FFPE Total RNA Miniprep System (Promega, Madison, WI, USA) and processed using the SensationPlus™ FFPE Amplification and 3′ IVT Labeling Kit (Thermo), followed by GeneChip Human Transcriptome Array 2.0 (Thermo) according to the manufacturer’s instructions. The CEL files were normalized and summarized at the gene level using SSTRMA algorithm from the TRANSCRIPTOME ANALYSIS CONSOLE software (Thermo). Normalized expression and DABG (detection above background) values were retrieved from the CHP files using the AFFYPARSER package. Five of the 30 FFPE blocks were newer, and a batch effect was observed for them. Thus, ComBat algorithm was used to remove batch effects (Leek et al., 2012). Transcript clusters with DABG ≥ 0.05 for all of the samples were excluded. Data were annotated according to the HTA20TRANSCRIPTCLUSTER.DB package in R. Only transcript clusters with a corresponding RefSeq ID for protein (‘NP’) were kept, and transcript clusters for the same gene were collapsed (based on max intensity) using the wgcna package (Langfelder and Horvath, 2008). For unsupervised hierarchical clustering, differentially expressed gene (DEG) analysis, and signature acquisition, the dataset was filtered to keep mRNAs with higher median intensity and standard deviation (sd) than the RSK1 mRNA. A total of 4562 genes were used for analysis. DEG was obtained using the limma package in R (Ritchie et al., 2015). DEGs were used as input for the GOstats package to determine the biological processes enriched in RSK1hi and RSK1lo groups (Falcon and Gentleman, 2007). As universe for GOstats, all mRNAs from the filtered dataset were used and a hypergeometric test was applied with a pvalueCut-off = 0.001.

2.6. Profiling of immune infiltrate based on transcriptome data

We used the estimate package to estimate the nontumoral fraction, and immune and stromal components for the 30 GBM samples (Yoshihara et al., 2013). The profiling of 22 immune-related cell types was performed using the LM22 gene signature for the CIBERSORT software (https://cibersort.stanford.edu/) (Newman et al., 2015). For CIBERSORT, the normalized transcriptome data were transformed by applying 2′ data. We disabled quantile normalization, and 1000 permutations were carried on. The relative formula of immune cells was corrected with the tumor purity estimation from the estimate analysis, to allow determination of the fraction of tumor represented by each cell type.

2.7. Determination of signature enrichment scores by GSVA

The Gene set variation analysis package for R was used with the following parameters: mx.diff = T and method = ‘gsva’ (Hänzelmann et al., 2013). Before using GSVA, mRNAs with a median intensity and sd below any mRNA from the signature were excluded. The GBM molecular subtype was determined using the gene sets provided in the GSEA webpage (http://software.broadinstitute.org/gsea) corresponding to the TCGA 2010 signatures (Verhaak et al., 2010). A newer (2016) set of signatures was reported by TCGA for IDH wild-type GBMs, where the neural subtype was eliminated (Ceccarelli et al., 2016).

2.8. TCGA datasets for gliomas

CEL files from GBM microarrays (GeneChip® HT Human Genome U133 Array Plate Set; Affymetrix, Santa Clara, CA, USA) were obtained from TCGA portal (https://portal.gdc.cancer.gov/) and processed using the aFFY (Gautier et al., 2004) package in R. Arrays were normalized and summarized by robust multi-array average (RMA), and the ComBat algorithm was used to remove batch effects (batch information was obtained from the TCGA batch effects website: https://bioinformatics.mdanderson.org/tcga mbatch/). Only batch effects for batches 1 and 79 were adjusted. GBMs from the same patients were averaged. Present/absent calls were obtained by the mas5calls function, and probes classified as absent for all the samples were filtered out. The data were annotated according to the HTGU133A.DB package for R. Only probes with a corresponding RefSeq ID for protein (‘NP’) were kept, and probes for the same gene were collapsed (based on max intensity) using the wgcna package. A total of 527 GBM samples were included in the analysis. For the analysis of the RSK1 signature among different grade gliomas, RNA-seq data from the TCGA portal (https://portal.gdc.cancer.gov/) were obtained for LGG (grades II and III) and grade IV (GBM). The data were annotated according to the org.Hs.eg.db package for R. Only probes with a corresponding RefSeq ID for protein (‘NP’) were kept, and reads for the same gene were collapsed (based on max intensity) using the wgcna package. We kept mRNAs with a maximum of 16 samples with 0 counts to maintain the RSK1 signature genes. The data were normalized by ‘Trimmed Mean of M-values’ from the edger (Robinson et al., 2009) package and voom transformed (limma package) before analysis. The number
of samples of the dataset was as follows: grade II = 216; grade III = 237; and GBM = 137. Normalized level 4 data from the reverse-phase protein array (RPPA) technique were downloaded from The Cancer Proteome Atlas (TCPA, https://tcpaportal.org/tcpa/index.html) for GBM. A total of 175 samples with corresponding RPPA and microarray data were used. For the analysis of P(T359/S363)-RSK1 and RSK1/2/3 in gliomas of different grades, we used normalized level 4 data from the pan-cancer study. The number of samples of the dataset was as follows: grade II = 123; grade III = 134; and GBM = 171.

2.9. Gravendeel dataset for gliomas

CEL files from microarrays (GeneChip™ Human Genome U133 Plus 2.0 Array; Affymetrix) associated with the study from Gravendeel et al. were obtained (GSE16011) and processed using the affy package in R. Only primary samples were analyzed. Arrays were normalized and summarized by RMA, and the ComBat algorithm was used to remove batch effects. Present/absent calls were obtained by the mas5calls function, and probes classified as absent for all the samples were filtered out. The data were annotated according to the HGU133PLU2.db package in R. Only probes with a corresponding RefSeq ID for protein (‘NP’) were kept, and probes for the same gene were collapsed (based on max intensity) using the WGCNA package. The dataset contains nontumor (NT) = 8, grade I = 8, grade II = 24, grade III = 85, and GBM = 152.

2.10. Overall patient survival analysis

Survival for ACCCC cohort was calculated using the date of the surgery as initial time, due to the lack of the date of image diagnostic for some of the samples. For the Recife cohort, consisting of recent cases, the image diagnosis date was available and used as initial time for survival calculation. The analysis and survival curves were performed using survminer and survival packages in R. We used the overall survival data for the definition of high- and low-expression groups (or enriched and underrepresented RSK1 signature groups). For RSK1 in the ACCCC, its expression levels (HSCORE) were analyzed regarding survival. Two cutoffs that minimized the P-value of a Fisher’s exact test were set: one dividing the samples in RSK1hi and RSK1lo, and the other in short and long survivors (Fig. 2A, Fig 3A). The latter corresponded to the longest survival time of the RSK1hi group. For the remaining markers, including RSK1 in the Recife cohort, we determined the log-rank test P-values for all the sets of two groups that can be formed according to expression (or signature enrichment) levels, where all the expression levels of the low-expression group are smaller than those of the high-expression group. Then, the distribution of samples that allowed lowest P-values while equilibrating the number of members in each group and maximizing the median-average survival differences was chosen. The separation of groups is indicated with a vertical line in the graphs of expression (or RSK1 signature enrichment) vs. survival. To calculate the Fisher’s exact test for markers of the ACCCC and Recife cohorts, the survival time cutoff was set to the longest survival time of the RSK1hi group. For the TCGA and Gravendeel cohorts, after the determination of the signature enrichment cutoff, the survival time limit was set as the one minimizing the P-value of a Fisher’s exact test. The censored samples below the survival time cutoff were not considered for the Fisher’s exact tests.

2.11. Statistical analysis

Kruskal–Wallis test followed by Dunn’s multiple comparison test was applied using the Dunn.test package in R. Univariate survival analyses were performed using the Kaplan–Meier estimator and the log-rank test (P-values are indicated in the plots), and median survival is shown in Table S2. Multivariate Cox regression analysis was performed with the survival package for R. In cases where proportional Hazards could not be assumed for a covariate (tested by the cox.zph function), univariate analysis was performed after stratification by that same covariate. Fisher’s exact test was used for significance testing in experiments with a 2 × 2 contingency table (P-values are indicated in the graphs). Pearson’s and Spearman’s coefficients for correlations are indicated in the graphs along with the P-values in parentheses. Values of $P < 0.05$ were considered significant. All statistical analysis was performed in RStudio with R version 3.5.1.

2.12. Graphics

Graphs were assembled using the ggplot2 package in RStudio with R version 3.5.1. For unsupervised hierarchical clustering, we used Pearson’s distance and average linkage. The dendrogram was optimized with the dendextend package (Galili, 2015). The heatmap2 function in R was used to generate the DEG heatmap. Default options were used for clustering. Appendix S1 includes additional information of R packages used in this article.
3. Results

3.1. RSK1, but not RSK2 or RSK3, protein levels are higher in grade IV gliomas

RSK1 protein levels were evaluated by IHC in a TMA containing NB and grade I-IV astrocytomas from the ACCCC. While the median RSK1 protein expression was higher in GBM (grade IV) cases than the median of NB and LGG (grades I-III) cases (Fig. 1A, Fig. S1A), only about half of GBMs showed higher RSK1 levels than NB and LGG. The other half of GBMs expressed RSK1 at levels comparable to the rest of the gliomas. A different subset of gliomas was tested for RSK1 protein by western blot showing an expression pattern compatible with the result of the TMA (Fig. S2A). On the other hand, RSK2 protein expression did not differ significantly among NB and the various grades of gliomas, showing overlapping distributions of intensities (Fig. 1B, Fig. S1B). While some samples present very low or undetectable levels of RSK1, RSK2 can be easily detected in low-expressing samples even by western blot (Fig. S2B). RSK3 isoform levels were very low when compared to RSK1 and RSK2, and GBMs show lower RSK3 levels than NB and LGG (Fig. 1C, Fig. S1C). Detection of RSK3 in gliomas by western blot required very long exposure times (Fig. S2C) and is consistent with the apparent lack of RSK3 expression in GBM cell lines (Roffé et al., 2015). We were not able to detect RSK4 in both gliomas (Fig. S2C) and GBM cell lines (Roffé et al., 2015) by western blot. The IDH1 mutation occurs frequently in grade II and III gliomas, and indeed, when considering only the samples positive for IDH1R132H (Fig. S1E), the median RSK1 levels were also higher in GBMs than in LGG (Fig. 1D). Also in IDH1 mutant samples, the levels of RSK2 and RSK3 were comparable between the grades (Fig. 1E,F). This strongly suggests that increase in the RSK1 isoform can also occur during progression of secondary GBMs.

We included in our analysis an antibody originally raised to detect RSK1 when it is phosphorylated at S380 (Fig. S1D, Fig. S2B). It can also detect RSK2 and RSK3 when phosphorylated at a homologous serine (according to the vendor; Cell Signaling). This phosphorylation is necessary for RSK activation (Anjum and Blenis, 2008). Median levels of RSK phosphorylation (S380) did not differ significantly among NB and the various grades of gliomas (Fig. 1G,H). However, high levels of P(S380)-RSK were detected in a subgroup of GBMs, consistent with the high levels of RSK1 observed. In addition, we evaluated P(T359/S363)-RSK1 levels, also required for activation (Anjum and Blenis, 2008), in grade II-IV gliomas using the RPPA data from TCGA (Brennan et al., 2013). According to Cell Signaling, the P(T359/S363)-RSK1 antibody (#9344) does not cross-react with RSK2 but can show some reaction with RSK3. Our analysis revealed increased levels of P(T359/S363)-RSK1 in GBMs (Fig. 1I). Since RSK3 is essentially absent, we can confirm that RSK1 activation is augmented in GBMs. In conclusion, increased RSK1 expression and activation is a feature that appears in a subgroup of GBMs.

The ACCCC cohort included three cases of recurrence with matched LGG and GBM samples. RSK1 expression levels increased after the recurrence in all the cases (Fig. 1J,K); however, RSK2, RSK3, and P(S380)-RSK levels did not (Fig. 1L–N). Altogether, these observations suggest that an isoform-specific RSK1 increase can occur during the progression of gliomas from low to high grade.

3.2. High RSK1 and RSK2 protein levels in GBM are associated with worse survival

RSK1 and RSK2 levels were analyzed relative to survival outcomes in GBMs. We found that the 26 (34.2%) GBMs expressing the highest levels of RSK1 did not survive more than 1.8 years (horizontal line in Fig. 2A, B), and named this group RSK1hi. The remaining 2/3 of GBMs (named RSK1lo group) included 14/50 cases with survival times longer than 1.8 years, seven of them being very long survivors (> 3 years). IDH1R132H mutation was higher in GBM (grade IV) cases than the median of NB and LGG (grades I-III) cases (Fig. 1A, Fig. S1A), only about half of GBMs showed higher RSK1 levels than NB and LGG. The other half of GBMs expressed RSK1 at levels comparable to the rest of the gliomas. A different subset of gliomas was tested for RSK1 protein by western blot showing an expression pattern compatible with the result of the TMA (Fig. S2A). On the other hand, RSK2 protein expression did not differ significantly among NB and the various grades of gliomas, showing overlapping distributions of intensities (Fig. 1B, Fig. S1B). While some samples present very low or undetectable levels of RSK1, RSK2 can be easily detected in low-expressing samples even by western blot (Fig. S2B). RSK3 isoform levels were very low when compared to RSK1 and RSK2, and GBMs show lower RSK3 levels than NB and LGG (Fig. 1C, Fig. S1C). Detection of RSK3 in gliomas by western blot required very long exposure times (Fig. S2C) and is consistent with the apparent lack of RSK3 expression in GBM cell lines (Roffé et al., 2015). We were not able to detect RSK4 in both gliomas (Fig. S2C) and GBM cell lines (Roffé et al., 2015) by western blot. The IDH1 mutation occurs frequently in grade II and III gliomas, and indeed, when considering only the samples positive for IDH1R132H (Fig. S1E), the median RSK1 levels were also higher in GBMs than in LGG (Fig. 1D). Also in IDH1 mutant samples, the levels of RSK2 and RSK3 were comparable between the grades (Fig. 1E,F). This strongly suggests that increase in the RSK1 isoform can also occur during progression of secondary GBMs.

We included in our analysis an antibody originally raised to detect RSK1 when it is phosphorylated at S380 (Fig. S1D, Fig. S2B). It can also detect RSK2 and RSK3 when phosphorylated at a homologous serine (according to the vendor; Cell Signaling). This phosphorylation is necessary for RSK activation (Anjum and Blenis, 2008). Median levels of RSK phosphorylation (S380) did not differ significantly among NB and the various grades of gliomas (Fig. 1G,H). However, high levels of P(S380)-RSK were detected in a subgroup of GBMs, consistent with the high levels of RSK1 observed. In addition, we evaluated P(T359/S363)-RSK1 levels, also required for activation (Anjum and Blenis, 2008), in grade II-IV gliomas using the RPPA data from TCGA (Brennan et al., 2013). According to Cell Signaling, the P(T359/S363)-RSK1 antibody (#9344) does not cross-react with RSK2 but can show some reaction with RSK3. Our analysis revealed increased levels of P(T359/S363)-RSK1 in GBMs (Fig. 1I). Since RSK3 is essentially absent, we can confirm that RSK1 activation is augmented in GBMs. In conclusion, increased RSK1 expression and activation is a feature that appears in a subgroup of GBMs.

The ACCCC cohort included three cases of recurrence with matched LGG and GBM samples. RSK1 expression levels increased after the recurrence in all the cases (Fig. 1J,K); however, RSK2, RSK3, and P(S380)-RSK levels did not (Fig. 1L–N). Altogether, these observations suggest that an isoform-specific RSK1 increase can occur during the progression of gliomas from low to high grade.

3.2. High RSK1 and RSK2 protein levels in GBM are associated with worse survival

RSK1 and RSK2 levels were analyzed relative to survival outcomes in GBMs. We found that the 26 (34.2%) GBMs expressing the highest levels of RSK1 did not survive more than 1.8 years (horizontal line in Fig. 2A, B), and named this group RSK1hi. The remaining 2/3 of GBMs (named RSK1lo group) included 14/50 cases with survival times longer than 1.8 years, seven of them being very long survivors (> 3 years). IDH1R132H mutation was higher in GBM (grade IV) cases than the median of NB and LGG (grades I-III) cases (Fig. 1A, Fig. S1A), only about half of GBMs showed higher RSK1 levels than NB and LGG. The other half of GBMs expressed RSK1 at levels comparable to the rest of the gliomas. A different subset of gliomas was tested for RSK1 protein by western blot showing an expression pattern compatible with the result of the TMA (Fig. S2A). On the other hand, RSK2 protein expression did not differ significantly among NB and the various grades of gliomas, showing overlaps...
Characterizing gliomas with high RSK1 expression levels

- **A** RSK1 protein expression (astrocytoma)
- **B** RSK2 protein expression (astrocytoma)
- **C** RSK3 protein expression (astrocytoma)
- **D** RSK1 in IDH1 mutants (astrocytoma)
- **E** RSK2 in IDH1 mutants (astrocytoma)
- **F** RSK3 in IDH1 mutants (astrocytoma)
- **G** RSK phosphorylation (S380) (astrocytoma)
- **H** P(S380)-RSK in IDH1 mutants (astrocytoma)
- **I** P(T359/S363)-RSK1 (Glioma - RPPA/TCGA)
- **J** RSK1 protein expression (recurrence)
- **K** RSK1 protein expression (recurrence)
- **L** RSK2 protein expression (recurrence)
- **M** RSK3 protein expression (recurrence)
- **N** RSK phosphorylation (S380) (recurrence)
Characterizing gliomas with high RSK1 expression levels

G. N. Hajj et al.
GBMs were present in the RSK1 hi group, suggesting that secondary GBMs can also express high RSK1 levels (Fig. S3A). The 29 GBMs expressing the highest RSK2 levels showed significantly worse survival than the remaining 44 (vertical line separates RSK2 groups in Fig. 2C,D). In contrast to RSK1 hi group (Fig. 2A), two of the 11 GBMs expressing the highest RSK2 levels showed survival >1.8 years. Although not significant, we observed that while 10/40 (25%) of RSK2 lo GBMs were IDH1 R132H, only 2/29 (6.9%) of RSK2 hi were IDH1 R132H (P Fisher = 0.0604; Fig. S3B). There was no correlation between RSK1 and RSK2 expression in GBMs, and while 16/29 (55.2%) of RSK2 hi GBMs belong to RSK1 hi group, 16/26 (61.5%) of RSK1 hi GBMs belong to RSK2 hi group (Fig. 2E). We could not apply a multivariate Cox analysis for RSK2 and RSK1 groups as covariates because it was not possible to assume proportional Hazards for RSK1 (P = 0.0101 for cox.zph function). However, RSK2 remained a significant predictor after stratification by RSK1 groups (Fig. S4A). Multivariate cox analysis indicated that RSK2 was an independent prognostic factor when adjusted for IDH1 R132H status (Fig. S4B) or chemotherapy (CTx), when the latter analysis was performed stratifying by radiotherapy (RTx; Fig. S4C). In conclusion, for this cohort, high levels of RSK1 were associated with the absence of long survivors and RSK2 was an independent predictor of poor survival.

P(S380)-RSK levels were higher in RSK1 hi group (median = 21.74) than in RSK1 lo (median = 9.81, P = 0.00067; Fig. 2F). Although less significant, P(S380)-RSK levels were also higher in RSK2 hi group (median = 19.15) than in RSK2 lo (median = 11.84, P = 0.0231; Fig. 2G). For P(S380)-RSK, we defined a group of 28/74 GBMs showing the highest phosphorylation levels while resulting in the lowest P-value for the Fisher’s exact test when considering 1.8 years as the limit for long and short survivors (vertical and horizontal lines in Figs S5A,B and S3C). 16/26 (61.5%) of RSK1 hi GBMs were also P(S380)-RSK hi, but only 10/47 (21.2%) of P(S380)-RSK lo GBMs were RSK1 hi (Fig. S5C). On the other hand, 15/29 (51.7%) of RSK2 hi GBMs were also P(S380)-RSK hi and 14/45 (31.1%) of P(S380)-RSK lo GBMs were RSK2 hi (Fig. S5D). Interestingly, 12/15 (80%) GBMs belonging to both RSK1 hi and RSK2 hi groups at the same time (RSK1 hi-RSK2 hi) were P(S380)-RSK hi, in contrast to the representation of P(S380)-RSK hi GBMs in RSK1 hi-RSK2 lo (3/10 or 30%), RSK1 lo-RSK2 hi (2/13 or 15.4%), and RSK1 lo-RSK2 lo (8/32 or 25%; Fig. 2H) subgroups. In fact, the P(S380)-RSK levels were significantly higher for RSK1 hi-RSK2 hi GBMs than for RSK1 lo-RSK2 lo and RSK1 lo-RSK2 hi subgroups. As mentioned above, P(T359/S363)-RSK1 levels (RPPA experiment—TCGA) in GBMs can be considered a measure of RSK1 activation. Accordingly, higher levels of P(T359/S363)-RSK1 were associated with a lower proportion of long survivors in GBMs from the TCGA cohort (Fig. S5E,F). In conclusion, high P(S380)-RSK levels (i.e., RSK activation) in GBMs were associated with high levels of both RSK1 and RSK2; however, the contribution of RSK1 was more important.

### 3.3. Transcriptomic characterization of RSK1 hi glioblastomas

Since the RSK1 hi group is composed of tumors that gained a new feature (high expression of RSK1), we further characterized their transcriptome. We performed both IHC for RSK1 and microarray analysis in FFPE sections of 30 GBM cases. Twenty-two of these samples were originally included in the TMA, and 8 were new samples (Table S1). As expected from the results of the TMA (Fig. 2A), we defined a RSK1 hi group consisting of 10/30 (30%) of the cases where none of the patients exceeded a survival time of...
Fig. 3. RSK1-associated transcriptome in GBMs. (A) RSK1 protein levels (HSCORE) for 30 GBM samples (ACCCC) relative to patient survival. The horizontal line indicates the longest survival time for RSK1hi group. The P-value of the Fisher’s exact test was calculated based on the four groups generated by the vertical and horizontal lines and is indicated. Status: 1 = dead; 0 = censored. (B) Comparison of protein and mRNA (microarray) RSK1 levels. (C) Relationship among RSK1 mRNA levels and survival. Colors indicate whether the samples belong to RSK1hi or RSK1lo groups. RSK1hi* and RSK1lo* samples showed ambiguity between RSK1 protein levels and transcription program. The vertical line indicates the cutoff for high- and low-expression groups, and the horizontal line indicates the longest survival time for RSK1hi group. The P-value of the Fisher’s exact test was calculated based on the four groups generated by the vertical and horizontal lines and is indicated. Status: 1 = dead; 0 = censored. (D) Unsupervised hierarchical clustering based on the transcriptome of the GBM samples. (E) Heatmap showing the DEGs between RSK1hi and RSK1lo groups (FDR < 0.015 and |logFC| ≥ 0.89). Clustering was performed using the DEGs. (F, G) The GSVA score indicating enrichment for each subtype is shown in (F) for TCGA 2010 and (G) TCGA 2016 signatures. CL, classical; ME, mesenchymal; NL, neural; nd: not determined; PN, proneural.
1.7 years (Fig. 3A, Fig. S6A). The mRNA levels for RSK1 obtained from the microarray correlated with protein levels (Fig. 3B). RSK1 mRNA expression allowed the separation in two groups with different overall survival; however, it did not allow for the determination of an RSK1-mRNA^hi_ group that

Fig. 4. RSK1 protein expression is associated with immune infiltrate in GBMs. (A) Biological processes enriched in RSK1^hi_ and RSK1^lo_ groups, obtained with the GOSTATS package. For this graph, biological processes with sizes of more than 500 or less than five genes were excluded. (B–D) Relationship between RSK1 protein expression (HSCORE) and (B) non-tumor fraction, (C) immune component, and (D) stromal component of GBMs. The ESTIMATE package was used. (E–N) The fraction of immune-related cells for each GBM was estimated by CIBERSORT using the LM22 signature. The immune cell types and their correlation with RSK1 protein expression are shown. Samples G10 and G24 are labeled in J.
excluded long survivors (Fig. 3C, Fig. S6B). The transcriptome data were used to perform an unsupervised hierarchical clustering (Fig. 3D) which revealed that RSK1 hi GBMs clustered together, reinforcing that high levels of RSK1 are indeed associated with a distinctive characteristic. Using two different sets of molecular classification signatures from TCGA (2010 and 2016), we observed that most of the RSK1 hi GBMs were classified as mesenchymal, but not all the mesenchymal GBMs were RSK1 hi (Fig. 3D). DEGs between the RSK1 hi and RSK1 lo groups were identified using the limma package in R (Table S3) (Ritchie et al., 2015). One RSK1 hi GBM that clustered with the RSK1 lo cases (RSK1 hi) and one RSK1 lo GBM that clustered with the RSK1 lo cases (RSK1 lo) were excluded from the analysis of DEGs due to their ambiguity. In Fig. 3E, DEGs are shown in a heatmap and it is evident that the RSK1 lo group could be further divided in two subclusters. Scores representing the enrichment of TCGA signatures for each subtype (GSVA scores) demonstrate that all of the RSK1 hi samples show a mesenchymal enrichment, even if the final classification differs, and the proneural signature is essentially absent (Fig. 3F,G).

3.4. Evidence of immune infiltration in RSK1 hi glioblastomas

We evaluated the biological processes associated with the RSK1 hi and RSK1 lo groups using the DEGs as input for the gostats package (Table S4) (Falcon and Gentleman, 2007). While the RSK1 hi group showed enrichment in immune-associated processes, RSK1 lo GBMs showed enrichment in processes of the nervous system (Fig. 4A). We next applied the estimate algorithm to estimate the nontumoral fraction of GBMs based on transcriptome data. Strikingly, RSK1 protein levels strongly correlated with the presence of nontumor components (Fig. 4B), being mainly composed of immune infiltrate (Fig. 4C). Of note, only 5/30 GBMs showed a positive score for stromal component (Fig. 4D). We performed a CIBERSORT analysis using the gene signature of 22 immune cell types (LM22) (Newman et al., 2015). The relative immune cell composition was corrected by the fraction of nontumor component from the Estimation package to calculate the contribution of each cell type to the tumor (Fig. 4E–N, Fig. S7). RSK1 protein expression was strongly correlated with the percent of activated natural killer (NK) cells (Fig. 4E). Other cell types that were found to correlate with RSK1 levels were macrophage M2 (Fig. 4G), neutrophils (Fig. 4I), resting-memory CD4 T cells (Fig. 4J), eosinophils (Fig. 4K), CD8 T cells (Fig. 4L), and activated mast cells (Fig. 4M). Two samples, G24 (RSK1 hi) and G10 (Fig. 3D), showed an exaggerated enrichment in resting-memory CD4 T cells pointing to mesenchymal GBMs with a different type of infiltrate (Fig. 4J). Essentially, no immune cell type was enriched in the RSK1 lo group.

3.5. RSK1 protein levels associate with LAPTM5 expression and CD68* infiltrate

An independent cohort of GBMs was included to confirm our observations (Recife cohort, Table S1). IHC for RSK1 (Fig. S8A) resulted in the same distribution regarding survival that we observed in the ACCCC cohort (compare Fig. 5A with Fig. 2A), suggesting the existence of three populations: (a) high RSK1 levels/short survival; (b) low RSK1 levels/short survival; and (c) low RSK1 levels/long survival. This casuistry showed a reduced proportion of short survivor cases in the RSK1 lo group when compared to the ACCCC cohort, and we could assume proportional Hazards. Thus, we defined an RSK1 hi group (24/47 cases) that excluded long survivors and showed worse survival than the RSK1 lo group (23/47 cases, Fig. 5B). The mRNA for LAPTM5 belongs to TCGA 2010 mesenchymal signature (Verhaak et al., 2010), and its function was related to the immune system (Glowacka et al., 2012; Ouchida et al., 2010; Ouchida et al., 2008). Since most RSK1 hi GBMs show mesenchymal signature enrichment, we decided to analyze LAPTM5 protein levels by IHC (Fig. S8B). We defined two groups according to LAPTM5 expression, where LAPTM5 hi GBMs showed worse survival; however, not all the long survivors were...
Characterizing gliomas with high RSK1 expression levels

A) RSK1 protein expression vs Survival (GBM - Recife cohort)

B) RSK1 protein expression (GBM)

C) LAPTM5 protein expression vs Survival (GBM - Recife cohort)

D) LAPTM5 protein expression (GBM)

E) CD68 protein expression vs Survival (GBM - Recife cohort)

F) CD68 protein expression (GBM)

G) RSK1, LAPTM5, DRAQ5, merge

H) RSK1, CD68, DRAQ5, merge
excluded from this group (Fig. 5C,D). Although RSK1 and LAPTM5 levels were highly correlated, we found a fraction (8/25; 32%) of RSK1hi GBMs being LAPTM5hi (Fig. S8D), reinforcing our suggestion that not all RSK1hi GBMs are mesenchymal. CD68 is considered a macrophage marker that in gliomas is mainly derived from M2 macrophages (Prosnia et al., 2013). However, CD68 can be expressed in other cell types (Gottfried et al., 2008). We defined two groups according to CD68 expression (Fig. S8C), where CD68hi GBMs showed worse survival (Fig. 5E,F). CD68 was also highly correlated with RSK1 levels and to a lesser degree with LAPTM5 (Fig. S8E,F). Alike the ACCCC cohort, IDH1 mutation was present in RSK1hi GBMs (Fig. S9A) as well as in the LAPTM5hi and CD68hi groups (Fig. S9B,C), suggesting that secondary GBMs can also express these markers. RSK1 expression levels remained an independent prognostic marker when adjusted for LAPTM5 or CD68 in a multivariate Cox analysis (Fig. S9D,E). RSK1 was also independent of RTx and CTx, which are known prognostic covariates for GBMs (Fig. S9F). One important question is whether immune infiltrate cells can contribute to RSK1 gain in GBMs. Double labeling for RSK1 and LAPTM5 in GBM tissues revealed widespread RSK1 labeling where most RSK1+ cells were also LAPTM5+ (Fig. 5G). In the case of CD68, RSK1+ cells included both CD68+ and CD68− (Fig. 5H, Fig. S10). This suggests that RSK1 gain can originate from both immune and GBM cells.

3.6. Validation of a RSK1 signature to explore datasets of glioblastomas

A second round of limma analysis with the previously determined DEGs for RSK1 groups (Fig. 3E) and including RSK1hi* and RSK1lo* samples was run to select a subpopulation of DEGs that better relates with the RSK1 protein levels. We evaluated the enrichment of subsets of upregulated mRNAs (logFC > 1.12, FDR < 0.022) in the 30 GBM samples and obtained a signature that allowed the separation between RSK1hi GBMs and long survivors (belonging to RSK1lo group) using transcriptomic data (Fig. 6A,B). This RSK1 signature allowed for the reclassification of samples from the RSK1lo group with RSK1 protein expression levels close to the cutoff (Fig. 6B). Accordingly, the survival of GBMs with higher GSVA scores, which indicates the signature enrichment, was significantly worse than GBMs with low GSVA score (compare Fig. 6C with Fig. S6A). The GSVA score was linearly related to RSK1 protein levels obtained by IHC (Fig. 6D) and, as expected, correlated to a lesser degree with RSK1 mRNA levels (Fig. 6E). From the 547 genes of the LM22 signature, 4 were present in the RSK1 signature, including CD68. From the 50 genes in TCGA 2016 mesenchymal signature, only THBS1 was present in the RSK1 signature. From the 216 genes in TCGA 2010 mesenchymal signature, six were present in the RSK1 signature, including LAPTM5 and THBS1. CHI3L1 was present in both LM22 and TCGA 2010 mesenchymal signatures (Fig. 6A).

Using the RSK1 signature, we explored two different previously published mRNA expression datasets of GBMs: TCGA (Brennan et al., 2013; McLendon et al., 2008; Verhaak et al., 2010) and Gravendeel (Gravendeel et al., 2009). The RSK1 signature (signRSK1) correlated with RSK1 mRNA levels in both datasets (Fig. 6F,G). Furthermore, the GBMs with higher GSVA scores showed worse survival (Fig. 6H,I) and long and very long survivors were underrepresented in the signRSK1enriched group. In the case of the Gravendeel dataset, cases with IDH1 mutation were present in GBMs with higher GSVA scores, but in a low
Characterizing gliomas with high RSK1 expression levels
proportion (Fig. S11A), resembling what we observed in the ACCCC (Fig. S3A) and Recife cohorts (Fig. S9A). However, in TCGA dataset, cases with IDH1 mutation were underrepresented in GBMs with higher GSVA scores (Fig. S11B). This apparent discrepancy can be the result of the selection of primary GBMs by the TCGA making IDH1 mutation infrequent in this cohort (Brennan et al., 2013). We observed that G-CIMP GBMs (hypermethylator phenotype) were less frequent in the signRSK1enriched group of GBMs in both datasets (Fig. S11C,D).

3.7. The RSK1 signature can determine poor survival even in low-grade gliomas

We further validated our RSK1 signature in LGG and GBM together. RSK1 signature was enriched in GBMs when compared to LGG from TCGA (Fig. 7A). With the Gravendeel dataset, we further demonstrated that the RSK1 signature was enriched in GBMs when compared with NB (Fig. 7B). Thus, the RSK1 signature recapitulated the IHC results obtained with the RSK1 antibody (Fig. 1A). Accordingly, in both datasets we observed that RSK1 mRNA levels behaved in the same direction as the RSK1 signature (Fig. 7C,D). We also analyzed the enrichment of RSK1 signature within grade II or grade III gliomas. In both datasets, signRSK1enriched grade III gliomas showed poor survival (Fig. 7E,F). The same was found for grade II gliomas from TCGA (Fig. 7G). We could not apply this analysis to the grade II gliomas from Gravendeel dataset due to an insufficient number of samples. These observations suggest that the RSK1 signature can predict RSK1-associated events even in LGG.

4. Discussion

Our data demonstrate that RSK1 protein levels above those expressed in nontumoral brain define a set of GBMs with clear features. Most of the RSK1hi GBMs were classified as part of the mesenchymal subtype based on TCGA signatures, which indicates that there exists an RSK1 isofrom preference that accompanies a specific gene expression program. Since high levels of RSK1 are practically absent from gliomas of lower grade, RSK1 increase can be considered a hallmark of the more malignant GBMs. This proposal is further supported by the exclusion of long and very long survivors from the RSK1hi group. Although IDH mutant cases can be found in the RSK1hi group, it is evident that the RSK1hi group is mainly composed of IDH wild-type and non-G-CIMP GBMs. Furthermore, the great majority of grade II and III gliomas, where IDH mutation is prevalent, did not show high levels of RSK1.

One of the main findings of our work was the close relationship between RSK1 protein expression and immune infiltrate. It was previously observed using the same set of 22 signatures for immune cell types, LM22 (Newman et al., 2015), that mesenchymal subtype GBMs showed enrichment in M2 macrophages, neutrophils, and resting-memory CD4 T-cell infiltrate (Wang et al., 2017). Accordingly, we also observed a correlation of those cell types with RSK1 protein levels; however, the most correlated type was activated NK cells. This suggests that RSK1-associated tumor infiltration has a partial overlap with that observed in the mesenchymal subtype. Confirming those observations, RSK1 protein levels highly correlated with the presence of CD68 in an independent GBM cohort. The presence of M2 macrophages is further indicated by the increase in RSK1hi GBMs of CD163 mRNAs (Table S3), a M2 macrophage marker (Zhou et al., 2015). In view of these findings, a critical question was raised on the origin of the high levels of RSK1 that appear in GBMs. Dual labeling of GBMs for RSK1 and CD68 showed that both CD68- (majority of cells) and CD68+ cells within the tumor express RSK1, which implies that RSK1 can indeed derive from both tumor and immune infiltrate cells. Accordingly, RSK1 expression was detected in GBM-derived cell lines (Roffé et al., 2015) and activated RSK1 can be observed in immune cells in vitro (Lin et al., 2008; Zaru et al., 2007). A more detailed investigation at the single cell level of GBMs, assayng different molecular markers of immune cells, will help to define the origin of RSK1. Immune system infiltration seems to play a fundamental role in the aggressiveness of the gliomas, and, accordingly, it has been proposed that a signature composed of immune-related genes can predict the risk of gliomas (Cheng et al., 2016). However, none of those genes were included in our RSK1 signature. In fact, the RSK1 signature that we used to infer RSK1 protein in datasets of GBM and LGG combines genes associated with immune infiltrate, such as CD68, with genes associated with mesenchymal subtype, such as LAPTMS. Nevertheless, only 10/33 genes in our signature were shared with the signatures used to predict immune cell types and GBM subtypes. In this manner, our work provides a different set of genes that can be helpful for the analysis of novel features of gliomas.

From the markers identified in this study, we observed that high protein levels of LAPTMS associate with worse survival in GBMs. LAPTMS is a transmembrane receptor associated with lysosomes and can...
Fig. 7. The RSK1 signature is enriched in grade IV gliomas. (A,B) GSVA scores for the enrichment in RSK1 signature (signRSK1) were obtained for gliomas of different grades from (A) TCGA and (B) Gravendeel datasets. NT = nontumor. The number of samples for each grade is indicated in parentheses. (C,D) Graphs showing the RSK1 mRNA levels for gliomas of different grades from (C) TCGA and (D) Gravendeel datasets. (E–G) Overall survival plots for (E) grade III (TCGA), (F) grade III (Gravendeel), and (G) grade II (TCGA) gliomas, comparing signRSK1^{enriched} vs. signRSK1^{underrepresented}. The number of samples is indicated in parentheses.
function as a modulator of the immune system. It has been proposed that LAPTM5 downregulates the expression of T- and B-cell receptors at the plasma membrane (Ouchida et al., 2010; Ouchida et al., 2008). In that manner, LAPTM5 might be a mechanism used by gliomas to negatively modulate the antitumoral response of the immune system. LAPTM5 has also been shown to be a proinflammatory regulator of macrophages (Glowacka et al., 2012). However, a recent report suggested that LAPTM5 is downregulated in human cancers, such as neuroblastoma, and that low levels of LAPTM5 are associated with poor prognosis (Nuylan et al., 2016). Our data suggest that LAPTM5 in GBMs show an opposite regulation to what has been observed in other tumor types.

We did not find differences in RSK2 expression between NB and gliomas I-IV. This finding disagrees with a previous report claiming that GBMs express more RSK2 protein than normal brain (Mathew et al., 2015). However, our conclusions are based on the expression levels of 189 samples, providing stronger support than the previous report that included two images, one for NB and one for GBM, with no further analysis. In the GBMs from our study, RSK2 protein levels were associated with worse survival and this might be related to its proposed role in migration/invasion in GBM-derived cell lines (Sulzmaier et al., 2016). It is important to note that about half of the RSK2\(^{hi}\) GBMs were also RSK1\(^{hi}\), which raises the possibility that high levels of RSK1 can define a different subset of GBMs, probably showing immune infiltration, even within the RSK2\(^{hi}\) group.

We previously showed that RSK3 and RSK4 isoforms are not detectable in two GBM-derived cell lines (Roffé et al., 2015). Accordingly, we did not detect RSK4 isoform in glioma samples. RSK3 protein expression was low in gliomas, and the higher levels were found in normal brain. In fact, GBMs show the lowest expression of RSK3. Interestingly, it has been suggested that both RSK3 and RSK4 can have tumor suppressor roles (Romeo et al., 2012). TCGA RPPA data also included an antibody that detects RSK1/2/3, and our analysis indicated that GBMs show reduced RSK1/2/3 levels when compared to LGG (Fig. S12A). One possibility is that RSK3 might be present in LGG and reduced in GBMs as observed with the RSK3 antibody, but without knowing the real contribution of each individual isoform for the reactivity of RSK1/2/3 antibody, it is impossible to derive any conclusions. Unlike RSK1 and RSK2, the RSK1/2/3 antibody showed no apparent relationship with survival in GBMs (Fig. S12B).

The levels of P(S380)-RSK were higher in RSK1\(^{hi}\) and, to a lesser extent, in RSK2\(^{hi}\) GBMs; however, the samples showing the highest phosphorylation levels were those bearing high RSK1 and RSK2 expression at the same time. This observation could be related to the proposed cross-reactivity of the P(S380)-RSK with P(S386)-RSK2, which precludes the determination of RSK activation at the isoform level. Analysis of the RPPA data for P(T359/S363)-RSK1 further confirmed that, in GBMs, RSK1 increases not only in expression but also in activity. In any case, our results point to the necessity of analyzing the RSK family at an isoform-specific level.

Our results have important implications that can eventually be translated to a clinical setting. RSK1 was the only RSK isoform that increased along with the grade of the gliomas and after recurrence. This strongly suggests that RSK1 levels and activity increase during glioma progression and might be involved in this process. Since the increase in RSK1 is accompanied by high levels of immune infiltration, its kinase activity might play a role in immune system modulation for GBM and LGG. Thus, RSK1 inhibition represents a promising goal for drug development in targeted therapies. Moreover, RSK1 protein expression can be used as a molecular marker to define a group of patients that almost certainly will have a short survival. Since RSK1 appears to be enriched in GBM but not NB, an appropriate NB control could be used as a reference for IHC reactions. Moreover, the RSK1 signature can be used not only in GBM but also in LGG to predict cases with poor survival. While RSK2 is expressed at comparable levels in NB and gliomas I to IV, gain of RSK1 is a feature that was only observed in GBMs. From a therapeutic point of view, RSK1-specific inhibition may prove useful for targeting only GBM cells and not nontumoral cells in RSK1\(^{hi}\) GBMs.

5. Conclusions

This study demonstrates that RSK1, but not RSK2 or RSK3, expression and RSK1 activation increase during glioma progression. Remarkably, long and very long survivors are essentially absent from the RSK1\(^{hi}\) group. Although RSK2 protein expression do not increase during glioma progression, high RSK2 levels are associated with worse survival and RSK2 behaves as an independent prognostic marker when adjusted for IDH1 mutation status and treatment. Transcriptome analysis indicated that RSK1\(^{hi}\) GBMs express mesenchymal subtype and immune infiltrate genes, showing enrichment for activated NK and M2 macrophage genes, as well as high levels of CD68 protein. An mRNA-based RSK1 signature could be used to
infer RSK1 protein levels in other glioma datasets. GBMs show enrichment in the RSK1 signature when compared to NB or LGG, further confirming the hypothesis that RSK1 expression might be gained during glioma progression together with immune infiltration. The RSK1 signature was related to worse survival in both GBMs and LGG. Thus, our results provide clinical and molecular basis to consider the kinase RSK1 as a promising biomarker and therapeutic target in gliomas.

Acknowledgements
This work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (2015/15451-3 to MR; 2018/17796-6 to GNH), Affymetrix Tumor-Proﬁling Grant 2015 (MR).

Conflict of interest
The authors declare no conﬂict of interest.

Data accessibility
The HTA 2.0 microarray data from this study were deposited in the NCBI Database of GEO with accession number GSE139380.

Author contributions
MR and GNH conceived and designed the experiments. MR and GNH analyzed the data. MR and FCSL prepared the RNA. MR performed the microarrays. FF and HMB performed IHC reactions. BB and FCSL prepared the RNA. MR performed the microarray expression analysis. MDB performed pathological anatomy analysis. CNCS, IVF, JRC, and LCT collected Recife’s cohort. PIS collected gliomas at the ACCCC for the western blot experiments. MR, GNH, and VRM wrote the manuscript.

References
Akhavan D, Cloughesy TF and Mishel PS (2010) mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12, 882–889.
Alvarenga AW, Coutinho-Camillo CM, Rodrigues BR, Rocha RM, Torres LFB, Martins VR, da Cunha IW and Hajj GNM (2013) A comparison between manual and automated evaluations of tissue microarray patterns of protein expression. J Histochem Cytochem 61, 272–282.

Characterizing gliomas with high RSK1 expression levels
Alvarenga AW, Machado LE, Rodrigues BR, Lupinacci FCS, Sanemastu P, Matta E, Roffe M, Torres LFB, da Cunha IW, Martins VR et al. (2017) Evaluation of Akt and RICTOR expression levels in astrocytomas of all grades. J Histochem Cytochem 65, 93–103.
Anjum R and Blenis J (2008) The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9, 747–758.
Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH et al. (2013) The somatic genomic landscape of glioblastoma. Cell 155, 462–477.
Cecarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM et al. (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550–563.
Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S and Wu A (2016) Bioinformatic profiling identiﬁes an immune-related risk signature for glioblastoma. Neurology 86, 2226–2234.
Falcon S and Gentleman R (2007) Using GOSstats to test gene lists for GO term association. Bioinformatics 23, 257–258.
Galili T (2015) dendextend: an R package for visualizing, adjusting and comparing trees of hierarchical clustering. Bioinformatics 31, 3718–3720.
Gautier L, Cope L, Bolstad BM and Irizarry RA (2004) Affy - analysis of affymetrix GeneChip data at the probe level. Bioinformatics 20, 307–315.
Glowacka WK, Alberts P, Ouchida R, Wang JY and Rotin D (2012) LAPT5 protein is a positive regulator of proinflammatory signaling pathways in macrophages. J Biol Chem 287, 27691–27702.
Gottfried E, Kunz-Schughart LA, Weber A, Rehli M, Peuker A, Müller A, Kastenberger M, Brockhoff G, Arendsee R and Kreutz M (2008) Expression of CD68 in non-myeloid cell types. Scand J Immunol 67, 453–463.
Gravendeel LAM, Kouwenhoven MCM, Gevaert O, De Rooi J, Stubbs AP, Duijff JE, Daemen A, Bleeker FE, Bralten LBC, Kloosterhof NK et al. (2009) Intrinsic gene expression proﬁles of gliomas are a better predictor of survival than histology. Cancer Res 69, 9065–9072.
Hänzelmann S, Castelo R and Guinney J (2013) GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 14.
Hatanaka Y, Hashizume K, Nitta K, Kato T, Itoh I and Tani Y (2003) Cytometrical image analysis for immunohistochemical hormone receptor status in breast carcinomas. Pathol Int 53, 693–699.
Houles T and Roux PP (2018) Deﬁning the role of the RSK isoforms in cancer. Semin Cancer Biol 48, 53–61.
Huse JT and Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. *Nat Rev Cancer* **10**, 319–331.

Langfelder P and Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* **9**, 559.

Leek JT, Johnson WE, Parker HS, Jaffe AE and Storey JD (2012) The SVA package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* **28**, 882–883.

Leinhart A, Luciani J and Maroudy D (2008) Malignant gliomas in adults. *N Engl J Med* **359**, 1850–1850.

Lin JX, Spolksi R and Leonard WJ (2008) Critical role for Rsk2 in T-lymphocyte activation. *Blood* **111**, 525–533.

Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Webster B, Hiroko KC, Wiestler OD, Kleihues P and Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol* **131**, 803–820.

Machado LE, Alvarenga AW, da Silva FF, Roffé M, Begnami MD, Torres LFB, da Cunha JW, Martins VR and Haji GN (2018) Overexpression of mTOR and p (240–244)S6 in IDH1 wild-type human glioblastomas is predictive of low survival. *J Histochem Cytochem* **66**, 403–414.

Mathew LK, Huangyang P, Mucaj V, Lee SS, Skuli N, Eisinger-Mathason TSK, Biju K, Li B, Venneti S, Lal P et al. (2015) Feedback circuitry between miR-28 and RTK activation in glioblastoma. *Sci Signal* **8**, ra42.

McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogonakis GM, Olson JJ, Mikkelsen T, Lehman N and Aldape K et al. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* **455**, 1061–1068.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods* **12**, 453–453.

Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* **17**, 510–522.

Nuñan M, Tatsuyuki K, Inazawa J and Inoue J (2016) Down-regulation of LAPT5M in human cancer cells. *Oncotarget* **7**, 28320–28328.

Ouchida R, Kurosaki T and Wang J-Y (2010) A role for lysosomal-associated protein transmembrane 5 in the negative regulation of surface B cell receptor levels and B cell activation. *J Immunol* **185**, 294–301.

Ouchida R, Yamasaki S, Hikida M, Masuda K, Kawamura K, Wada A, Mochizuki S, Tagawa M, Sakamoto A, Hatano M et al. (2008) A lysosomal protein negatively regulates surface T cell antigen receptor expression by promoting CD3ζ-chain degradation. *Immunity* **29**, 33–43.

Prosniai M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT, Cotzia P and Hooper DC (2013) Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. *Clin Cancer Res* **19**, 3776–3786.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* **43**, e47.

Robinson MD, McCarthy DJ and Smyth GK (2009) edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140.

Roffé M, Lupinacci FC, Soares LC, Haji GN and Martins VR (2015) Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner. *Cell Signal* **27**, 1630–1642.

Romeo Y, Zhang X and Roux PP (2012) Regulation and function of the RSK family of protein kinases. *Biochem J* **441**, 553–569.

Sulziatma FJ, Young-Robbins S, Jiang P, Geerts D, Prechtl AM, Matter MLML, Kesaris S and Ramos JW (2016) RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics. *Oncotarget* **7**, 79869–79884.

Turkalp Z, Karamchandani J and Das S (2014) IDH mutation in glioma: New insights and promises for the future. *JAMA Neurol* **71**, 1319–1325.

Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T and Mesirov JP et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* **17**, 98–110.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y et al. (2017) Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. *Cancer Cell* **32**, 42–56.e6.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA et al. (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. *Nat Commun* **4**, 2612.
cells and is activated through two distinct pathways. *Nat Immunol* 8, 1227–1235.

Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X et al. (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. *Nat Cell Biol* 17, 170–182.

Zong H, Parada LF and Baker SJ (2015) Cell of origin for malignant gliomas and its implication in therapeutic development. *Cold Spring Harb Perspect Biol* 7, a020610.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig S1.** Expression of RSK isoforms in GBMs of the ACCCC cohort.

**Fig S2.** Western blot for RSK isoforms in gliomas.

**Fig S3.** Expression of RSK isoforms in GBMs and its relationship with survival and IDH1 mutation status.

**Fig S4.** Multivariate analysis for RSK2 in GBMs of the ACCCC cohort.

**Fig S5.** Analysis of RSK phosphorylation in GBMs of the ACCCC cohort.

**Fig S6.** Survival curves for the 30 GBM cases from the ACCCC cohort used for transcriptome.

**Fig S7.** Immune-cell composition of RSK1hi and RSK1lo GBMs.

**Fig S8.** Expression of RSK1, LAPTSM and CD68 in GBMs of the Recife cohort.

**Fig S9.** RSK1 relationship with prognostic markers in GBMs of the Recife cohort.

**Fig S10.** RSK1 and CD68 expression in cells of GBM tissue.

**Fig S11.** IDH1 mutation and G-CIMP status in RSK1 signature-enriched GBMs.

**Fig S12.** Analysis of reverse phase protein array (RPPA) data (TCGA) for RSK1/2/3 antibody in LGGs and GBM.

**Table S1.** Clinical information of cohorts used in the present study (excel file).

**Table S2.** Median survival information for the overall-survival plots in the article.

**Table S3.** DEGs between RSK1hi and RSK1lo GBMs (excel file).

**Table S4.** Complete list of biological processes obtained by the GOstats package (excel file).

**Appendix S1.** Additional information of R packages used in this article.